| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,590,000 |
| Market
Cap: |
2.44(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$26.98 - $26.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Myovant Sciences is a biopharmaceutical company. Co. has two U.S. Food and Drug Administration-approved products, which consist of: ORGOVYX® (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with prostate cancer; and MYFEMBREE® (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), an oral GnRH treatment for the management of heavy menstrual bleeding associated with uterine fibroids. Co.'s MYFEMBREE is being evaluated for contraceptive ability in women with heavy menstrual bleeding associated with uterine fibroids or endometriosis-associated pain who are 18 to 50 years of age and at risk for pregnancy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
51,599,200 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,393,178,400 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
107,215 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,154,122 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
22 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ferreira Juan Camilo Arjona |
Chief Medical Officer |
• – – |
2023-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(246,684) |
0 |
|
- |
|
| Lang Matthew |
General Counsel & Corp. Secy. |
• – – |
2023-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(354,303) |
0 |
|
- |
|
| Potter Myrtle S |
Director |
– • – |
2023-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,673) |
0 |
|
- |
|
| Marek David C |
Principal Executive Officer |
• • – |
2023-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(417,599) |
0 |
|
- |
|
| Curran Terrie |
Director |
– • – |
2023-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,673) |
0 |
|
- |
|
| Valente Nancy |
Director |
– • – |
2023-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,673) |
0 |
|
- |
|
| Sumitovant Biopharma Ltd. |
10% Owner |
– – • |
2023-03-10 |
4 |
B |
$27.00 |
$1,393,178,400 |
I/I |
51,599,200 |
45,798,176 |
1.5 |
- |
|
| Mehra Uneek |
Principal Financial Officer |
• – – |
2023-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(202,696) |
0 |
|
- |
|
| Guinan Mark |
Director |
– • – |
2023-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,673) |
0 |
|
- |
|
| Gulfo Adele M. |
Director |
– • – |
2023-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,673) |
0 |
|
- |
|
| Merendino Lauren |
Chief Commercial Officer |
• – – |
2023-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(169,538) |
0 |
|
- |
|
| Sumitovant Biopharma Ltd. |
10% Owner |
– – • |
2023-03-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,243,005) |
45,798,176 |
|
- |
|
| Lang Matthew |
General Counsel & Corp. Secy. |
• – – |
2023-01-18 |
4 |
S |
$26.89 |
$34,204 |
D/D |
(1,272) |
354,303 |
|
-0% |
|
| Marek David C |
Principal Executive Officer |
• • – |
2023-01-18 |
4 |
S |
$26.89 |
$216,115 |
D/D |
(8,037) |
417,599 |
|
-0% |
|
| Ferreira Juan Camilo Arjona |
Chief Medical Officer |
• – – |
2023-01-18 |
4 |
S |
$26.89 |
$29,821 |
D/D |
(1,109) |
246,684 |
|
-0% |
|
| Merendino Lauren |
Chief Commercial Officer |
• – – |
2023-01-18 |
4 |
S |
$26.89 |
$53,995 |
D/D |
(2,008) |
169,538 |
|
-0% |
|
| Ferreira Juan Camilo Arjona |
Chief Medical Officer |
• – – |
2023-01-04 |
4 |
S |
$26.90 |
$60,552 |
D/D |
(2,251) |
247,793 |
|
-0% |
|
| Lang Matthew |
General Counsel & Corp. Secy. |
• – – |
2023-01-04 |
4 |
S |
$26.90 |
$74,755 |
D/D |
(2,779) |
355,575 |
|
-0% |
|
| Mehra Uneek |
Principal Financial Officer |
• – – |
2022-12-16 |
4 |
S |
$26.75 |
$59,947 |
D/D |
(2,241) |
202,696 |
|
-0% |
|
| Lang Matthew |
General Counsel & Corp. Secy. |
• – – |
2022-10-18 |
4 |
S |
$25.20 |
$48,712 |
D/D |
(1,933) |
358,354 |
|
-10% |
|
| Merendino Lauren |
Chief Commercial Officer |
• – – |
2022-10-18 |
4 |
S |
$25.20 |
$42,916 |
D/D |
(1,703) |
171,546 |
|
-10% |
|
| Marek David C |
Principal Executive Officer |
• • – |
2022-10-18 |
4 |
S |
$25.20 |
$281,131 |
D/D |
(11,156) |
425,636 |
|
-10% |
|
| Ferreira Juan Camilo Arjona |
Chief Medical Officer |
• – – |
2022-10-18 |
4 |
S |
$25.20 |
$40,421 |
D/D |
(1,604) |
250,044 |
|
-10% |
|
| Ferreira Juan Camilo Arjona |
Chief Medical Officer |
• – – |
2022-10-04 |
4 |
S |
$24.40 |
$66,807 |
D/D |
(2,738) |
251,648 |
|
-6% |
|
| Lang Matthew |
General Counsel & Corp. Secy. |
• – – |
2022-10-04 |
4 |
S |
$24.40 |
$89,768 |
D/D |
(3,679) |
360,287 |
|
-6% |
|
292 Records found
|
|
Page 1 of 12 |
|
|
